129 related articles for article (PubMed ID: 36443927)
1. Two effective models based on comprehensive lipidomics and metabolomics can distinguish BC versus HCs, and TNBC versus non-TNBC.
Jin Y; Fan S; Jiang W; Zhang J; Yang L; Xiao J; An H; Ren L
Proteomics Clin Appl; 2023 May; 17(3):e2200042. PubMed ID: 36443927
[TBL] [Abstract][Full Text] [Related]
2. Triple Negative Breast Cancer Detection Using LC-MS/MS Lipidomic Profiling.
Eghlimi R; Shi X; Hrovat J; Xi B; Gu H
J Proteome Res; 2020 Jun; 19(6):2367-2378. PubMed ID: 32397718
[TBL] [Abstract][Full Text] [Related]
3. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
4. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
5. Integration of metabolomics and lipidomics reveals serum biomarkers for systemic lupus erythematosus with different organs involvement.
Zhang W; Zhao H; Du P; Cui H; Lu S; Xiang Z; Lu Q; Jia S; Zhao M
Clin Immunol; 2022 Aug; 241():109057. PubMed ID: 35667550
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
7. LC-MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells.
Estrada-Pérez AR; Bakalara N; García-Vázquez JB; Rosales-Hernández MC; Fernández-Pomares C; Correa-Basurto J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292927
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
9. NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
He X; Gu J; Zou D; Yang H; Zhang Y; Ding Y; Teng L
Front Mol Biosci; 2021; 8():708052. PubMed ID: 34796199
[TBL] [Abstract][Full Text] [Related]
10. Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.
Li R; Xia Y; Chen X; Li X; Huang G; Peng X; Liu K; Zhang C; Li M; Lin Y; Dong J; Ji L; Lai Y
Transl Cancer Res; 2022 May; 11(5):1005-1016. PubMed ID: 35706801
[TBL] [Abstract][Full Text] [Related]
11. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.
He Y; Xiao B; Lei T; Xuan J; Zhu Y; Kuang Z; Liu J; He J; Li L; Sun Z
Gene; 2023 Apr; 860():147227. PubMed ID: 36709879
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
14. Radiomic analysis on magnetic resonance diffusion weighted image in distinguishing triple-negative breast cancer from other subtypes: a feasibility study.
Wang Q; Mao N; Liu M; Shi Y; Ma H; Dong J; Zhang X; Duan S; Wang B; Xie H
Clin Imaging; 2021 Apr; 72():136-141. PubMed ID: 33242692
[TBL] [Abstract][Full Text] [Related]
15. [Proton nuclear magnetic resonance spectroscopy recognition of metabolic patterns in fecal extracts for early diagnosis of colorectal cancer].
Lin Y; Wang ZN; Ma CC; Liu CK; Yang JR; Shen ZW; Wu RH
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Sep; 50(9):788-793. PubMed ID: 27655598
[No Abstract] [Full Text] [Related]
16. Use of cellular metabolomics and lipidomics to decipher the mechanism of Huachansu injection-based intervention against human hepatocellular carcinoma cells.
Wu H; Cheng H; Luo S; Peng C; Zhou A; Chen Z; Wu H; Li Q
J Pharm Biomed Anal; 2022 Apr; 212():114654. PubMed ID: 35158184
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of radiomics technology based on X-ray mammography in patients with triple-negative breast cancer.
Zhang HX; Sun ZQ; Cheng YG; Mao GQ
J Xray Sci Technol; 2019; 27(3):485-492. PubMed ID: 31081797
[TBL] [Abstract][Full Text] [Related]
18. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
19. An integrative approach based on GC-qMS and NMR metabolomics data as a comprehensive strategy to search potential breast cancer biomarkers.
Silva CL; Perestrelo R; Capelinha F; Tomás H; Câmara JS
Metabolomics; 2021 Aug; 17(8):72. PubMed ID: 34389918
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
Li M; Zhou Y; Xia T; Zhou X; Huang Z; Zhang H; Zhu W; Ding Q; Wang S
Breast Cancer Res Treat; 2018 Jul; 170(2):257-270. PubMed ID: 29557526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
